Movement Alert｜WuXi XDC Rises 3.24% in Regular Trading, BOCOM International Recommendation and Subsidiary Order Continue to Boost Sentiment

Market Focus

Jun 23

On June 23, WuXi XDC rose 3.24% in regular trading, trading at 49.38 HKD/share, with turnover of approximately HKD 106 million. The stock has posted gains for multiple consecutive sessions driven by a combination of broker endorsement and subsidiary business developments.

On the news front, BOCOM International recently issued a research report highlighting WuXi XDC as a top recommendation among leading players in high-growth biotech service tracks, citing strong investment value. Additionally, the company's controlled subsidiary Topharma signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharma will provide process development and manufacturing services for 10 batches of monoclonal antibody intermediates at RMB 1.9 million per batch, totaling RMB 19 million. The agreement is expected to help Topharma deepen its technical know-how, enhance process capabilities, and support future business expansion.

Within the Life Sciences Tools & Services sector, peers also traded higher, with Insilico up 6.05%, XtalPi up 3.71%, GenScript Biotech up 2.72%, WuXi Biologics up 2.28%, and WuXi AppTec up 0.9%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1195252736"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195252736\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1195252736?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195252736","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi XDC Rises 3.24% in Regular Trading, BOCOM International Recommendation and Subsidiary Order Continue to Boost Sentiment","media":"Market Focus","content":"<p><p>On June 23, WuXi XDC rose 3.24% in regular trading, trading at 49.38 HKD/share, with turnover of approximately HKD 106 million. The stock has posted gains for multiple consecutive sessions driven by a combination of broker endorsement and subsidiary business developments.</p><p>On the news front, BOCOM International recently issued a research report highlighting WuXi XDC as a top recommendation among leading players in high-growth biotech service tracks, citing strong investment value. Additionally, the company's controlled subsidiary Topharma signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharma will provide process development and manufacturing services for 10 batches of monoclonal antibody intermediates at RMB 1.9 million per batch, totaling RMB 19 million. The agreement is expected to help Topharma deepen its technical know-how, enhance process capabilities, and support future business expansion.</p><p>Within the Life Sciences Tools & Services sector, peers also traded higher, with Insilico up 6.05%, XtalPi up 3.71%, GenScript Biotech up 2.72%, WuXi Biologics up 2.28%, and WuXi AppTec up 0.9%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi XDC Rises 3.24% in Regular Trading, BOCOM International Recommendation and Subsidiary Order Continue to Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi XDC Rises 3.24% in Regular Trading, BOCOM International Recommendation and Subsidiary Order Continue to Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, WuXi XDC rose 3.24% in regular trading, trading at 49.38 HKD/share, with turnover of approximately HKD 106 million. The stock has posted gains for multiple consecutive sessions driven by a combination of broker endorsement and subsidiary business developments.</p><p>On the news front, BOCOM International recently issued a research report highlighting WuXi XDC as a top recommendation among leading players in high-growth biotech service tracks, citing strong investment value. Additionally, the company's controlled subsidiary Topharma signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharma will provide process development and manufacturing services for 10 batches of monoclonal antibody intermediates at RMB 1.9 million per batch, totaling RMB 19 million. The agreement is expected to help Topharma deepen its technical know-how, enhance process capabilities, and support future business expansion.</p><p>Within the Life Sciences Tools & Services sector, peers also traded higher, with Insilico up 6.05%, XtalPi up 3.71%, GenScript Biotech up 2.72%, WuXi Biologics up 2.28%, and WuXi AppTec up 0.9%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1195252736","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195252736","pubTimestamp":1782179712,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, WuXi XDC rose 3.24% in regular trading, trading at 49.38 HKD/share, with turnover of approximately HKD 106 million. The stock has posted gains for multiple consecutive sessions driven by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"动向提示|无锡XDC常规交易涨3.24%交银国际推荐及子公司订单持续提振人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On June 23, WuXi XDC rose 3.24% in regular trading, trading at 49.38 HKD/share, with turnover of approximately HKD 106 million. The stock has posted gains for multiple consecutive sessions driven by a combination of broker endorsement and subsidiary business developments.On the news front, BOCOM International recently issued a research report highlighting WuXi XDC as a top recommendation among leading players in high-growth biotech service tracks, citing strong investment value. Additionally, the company's controlled subsidiary Topharma signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharma will provide process development and manufacturing services for 10 batches of monoclonal antibody intermediates at RMB 1.9 million per batch, totaling RMB 19 million. The agreement is expected to help Topharma deepen its technical know-how, enhance process capabilities, and support future business expansion.Within the Life Sciences Tools & Services sector, peers also traded higher, with Insilico up 6.05%, XtalPi up 3.71%, GenScript Biotech up 2.72%, WuXi Biologics up 2.28%, and WuXi AppTec up 0.9%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}